Xue Yi

Xue Yi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2024 in Micromachines
Verified
Journal Article
Open access
PDF file
JCJiming Chen
Jiming Chen
MZMeiyu Zheng
Meiyu Zheng
QXQiaoling Xiao
Qiaoling Xiao
HWHui Wang
Hui Wang
CCCaixing Chi
Caixing Chi
LZLin Zhu
Lin Zhu
Extracellular vesicles (EVs) serve as vital messengers, facilitating communication between cells, and exhibit tremendous potential in the diagnosis and treatment of diseases. However, conventional EV isolation methods are labor-intensive, and they harvest EVs with low purity and compromised recovery. In addition, the drawbacks, such as the limited sensitivity and specificity of traditional EV analysis methods, hinder the application of EVs in clinical use. Therefore, it is urgent to develop effective and standardized methods for isolating and detecting EVs. Microfluidics technology is a powerful and rapidly developing technology that has been introduced as a potential solution for the above bottlenecks. It holds the advantages of high integration, short analysis time, and low consumption of samples and reagents. In this review, we summarize the traditional techniques alongside microfluidic-based methodologies for the isolation and detection of EVs. We emphasize the distinct advantages of microfluidic technology in enhancing the capture efficiency and precise targeting of extracellular vesicles (EVs). We also explore its analytical role in targeted detection. Furthermore, this review highlights the transformative impact of microfluidic technology on EV analysis, with the potential to achieve automated and high-throughput EV detection in clinical samples.

Verified
Journal Article
Open access
PDF file
YLYing Li
Ying Li
CWChuang Wu
Chuang Wu
RYRui Yang
Rui Yang
JTJiannan Tang
Jiannan Tang
ZLZhanqing Li
Zhanqing Li
ZFZhongxiong Fan
Zhongxiong Fan
Ischemic stroke is a serious neurological disease involving multiple complex physiological processes, including vascular obstruction, brain tissue ischemia, impaired energy metabolism, cell death, impaired ion pump function, and inflammatory response. In recent years, there has been significant interest in cell membrane-functionalized biomimetic nanoparticles as a novel therapeutic approach. This review comprehensively explores the mechanisms and importance of using these nanoparticles to treat acute ischemic stroke with a special emphasis on their potential for actively targeting therapies through cell membranes. We provide an overview of the pathophysiology of ischemic stroke and present advances in the study of biomimetic nanoparticles, emphasizing their potential for drug delivery and precision-targeted therapy. This paper focuses on bio-nanoparticles encapsulated in bionic cell membranes to target ischemic stroke treatment. It highlights the mechanism of action and research progress regarding different types of cell membrane-functionalized bi-onic nanoparticles such as erythrocytes, neutrophils, platelets, exosomes, macrophages, and neural stem cells in treating ischemic stroke while emphasizing their potential to improve brain tissue’s ischemic state and attenuate neurological damage and dysfunction. Through an in-depth exploration of the potential benefits provided by cell membrane-functionalized biomimetic nanoparticles to improve brain tissue’s ischemic state while reducing neurological injury and dysfunction, this study also provides comprehensive research on neural stem cells’ potential along with that of cell membrane-functionalized biomimetic nanoparticles to ameliorate neurological injury and dysfunction. However, it is undeniable that there are still some challenges and limitations in terms of biocompatibility, safety, and practical applications for clinical translation.

13 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
JCJiming Chen
Jiming Chen
MZMeiyu Zheng
Meiyu Zheng
QXQiaoling Xiao
Qiaoling Xiao
HWHui Wang
Hui Wang
CCCaixing Chi
Caixing Chi
LZLin Zhu
Lin Zhu
Extracellular vesicles (EVs) hold enormous potential in the diagnosis and treatment of diseases, benefit from their roles in intercellular signaling, as well as their plentiful presence and stability in body fluids. However, conventional EV isolation methods are labor-intensive, and harvest EVs with low purity and compromised recovery. In addition, the drawbacks, such as limited sensitivity and specificity of traditional EV analysis methods hinder the application of EVs in clinical use. Therefore, it is urgent to develop effective and standardized methods for isolating and detecting EVs. Microfluidics technology is a powerful and rapidly developing technology that has been introduced as a potential solution for the above bottlenecks. It holds the advantages of high integration, short analysis time, low consumption of samples and reagents. In this review, we summarize the traditional techniques alongside microfluidic-based methodologies for the isolation and detection of EVs. We emphasize the separation advantages of microfluidic technology in enhancing EV capture efficiency and precise targeting, while summarizing its analytical role in targeted detection and discussing the significance of EV detection in the tumor microenvironment, providing a direction for achieving automated and high-throughput EV detection in clinical samples.

21 February 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JWJing Wu
Jing Wu
BZBingyu Zhang
Bingyu Zhang
WDWei Du
Wei Du
YSYimin Shi
Yimin Shi
CXChunhong Xie
Chunhong Xie
XYXue Yi
Xue Yi
Silicosis, a disease characterized by fibrous changes in lung tissue due to prolonged silica dust inhalation, exhibits a complex pathogenesis that remains inadequately addressed by current interventions. Although osteoclast stimulatory transmembrane protein (OC-STAMP) is implicated in Silicosis progression, its regulatory mechanisms are not fully understood. In this study, we detected elevated OC-STAMP expression in Silicosis patients and found that treatment with OC-STAMP siRNA can alleviate the progression of Silicosis in mice, suggesting the potential of OC-STAMP as a diagnostic and therapeutic target for Silicosis. First, rat models of Silicosis were developed at various stages. A suite of histological and molecular techniques, including Hematoxylin and eosin (HE), Masson, Prussian blue staining, and immunohistochemistry, along with real-time polymerase chain reaction (RT-PCR), were employed to assess the expression levels of OC-STAMP, as well as indicators of ferroptosis and fibrosis.Second, MLE-12 cells were cultured in vitro to establish an OC-STAMP overexpression model, and the relationship between OC-STAMP and ferroptosis was evaluated using flow cytometry, and western blotting. Subsequently, to verify the role of OC-STAMP and ferroptosis in Silicosis progression, we administered OC-STAMP siRNA and Fer-1 to Silicosis mice respectively. Whole-body volumetric plethysmography (WBP) was utilized to assess the respiratory function of the mice, and Micro-CT was applied to detect the lung nodules in the mice. The levels of OC-STAMP, as well as indexes associated with ferroptosis and fibrosis, were assessed using Hematoxylin and eosin (HE), Masson, Sirius red staining, immunohistochemistry, and western blot analysis. The polarization of macrophages towards M1 and M2 phenotypes in lung tissues was analyzed by flow cytometry. Ultimately, the plasma expression of OC-STAMP in patients diagnosed with Silicosis was quantified using enzyme-linked immunosorbent assay (ELISA). In vivo experiments showed that OC-STAMP accelerates the fibrotic process of Silicosis, which may promote the epithelial-mesenchymal transformation by triggering ferroptosis of alveolar type II epithelial cells, and thus promote the progression of Silicosis. Furthermore, in vitro studies indicated that OC-STAMP overexpression causes ferroptosis in alveolar type II epithelial cells which contributes to fibrosis. Notably, treatment with siRNA in Silicosis mice confirmed that OC-STAMP inhibition effectively mitigates ferroptosis and retarded the progression of Silicosis fibrosis. Plasma of patients with Silicosis exhibited elevated OC-STAMP levels. Overall, OC-STAMP induces ferroptosis and exacerbates fibrosis in Silicosis. OC-STAMP siRNA and Fer-1 mitigate abnormal collagen deposition and delay the progression of Silicosis. Collectively, these findings highlight the potential of OC-STAMP as a novel biomarker for diagnosing and treating Silicosis.

14 January 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
WDWei Du
Wei Du
XWXiao-Wei Wu
Xiao-Wei Wu
QLQing-Feng Li
Qing-Feng Li
BZBing-Yu Zhang
Bing-Yu Zhang
JWJing Wu
Jing Wu
XYXue Yi
Xue Yi
The prognosis and treatment efficacy of lung adenocarcinoma (LUAD), a disease with a high incidence, remains unsatisfactory. Identifying new biomarkers and therapeutic targets for LUAD is essential. Chromosomal assembly factor 1B (CHAF1B), a p60 component of the CAF-1 complex, is closely linked to tumor incidence and cell proliferation. However, CHAF1B's biological role and molecular mechanism in LUAD remain unclear. Here, CHAF1B expression in LUAD was examined using the GEPIA2 and UALCAN databases. Using The Cancer Genome Atlas (TCGA) LUAD database, we analyzed the diagnostic and prognostic significance of CHAF1B and its association with immune infiltration and immunological checkpoints. Gene ontology (GO) enrichment and single-cell function analyses were employed to investigate CHAF1B's possible biological roles. Drug sensitivity analysis predicted CHAF1B's effect on chemotherapeutic drug sensitivity. We also predicted lncRNAs-miRNA-CHAF1B axis to explore the molecular mechanism of CHAF1B in LUAD. Preliminary in vitro studies using qRT-PCR, CCK8, Transwell, glucose, and lactate metabolism confirmed CHAF1B's expression and role in LUAD. Its expression is associated with drug sensitivity, immunological checkpoints, and immune cell infiltration. We predicted that three miRNAs (miR-29c-3p, miR-145-5p, miR-1247-5p) and three lncRNAs (AL139287.1, NEAT1, SHG1) may be target miRNAs and target lncRNAs that regulate CHAF1B. In vitro tests showed that CHAF1B suppression decreased LUAD's migration, invasion, proliferation, and glycolysis. Overall, CHAF1B may be an innovative biomarker and therapeutic target for LUAD.

10 April 2026 in PLOS ONE
Verified
Journal Article
Open access
JWJing Wu
Jing Wu
HKHaseeb Khaliq
Haseeb Khaliq
YKYanyan Ke
Yanyan Ke
Qudrat UllahQudrat Ullah
Qudrat Ullah
SSSheikh Arslan Sehgal
Sheikh Arslan Sehgal
XYXue Yi
Xue Yi
Pirfenidone, an antifibrotic agent, has been shown to be effective in the treatment of idiopathic pulmonary fibrosis (IPF). However, the exact mechanism of action and clinical efficacy require further investigation and validation. This study commenced by identifying pathogenic genes associated with IPF through the GeneCards database. Potential targets of pirfenidone were subsequently screened through PubChem and Swiss TargetPrediction, and overlapping targets were identified through Venn diagram analysis. Enrichment analysis of potential target genes was performed to identify the key biological processes and pathways involved in the action of pirfenidone. The main target genes were subsequently identified through the GSE10667 and GSE110147 datasets. The affinity of PDE1A to pirfenidone was predicted by molecular docking and MicroScale Thermophoresis (MST). Finally, the expression and antifibrotic effects of pirfenidone on PDE1A were validated through data from the GSE226249 dataset. PDE1A, identified by GeneCards and Swiss TargetPrediction, was found to be an important mediator of the antifibrotic effect of pirfenidone. The enrichment analysis revealed biological processes such as cyclic nucleotide-mediated signaling and cAMP-mediated signaling. KEGG pathway analysis further linked pirfenidone activity to pathways involved in calcium signaling, taste transduction, morphine dependence, renin secretion and purine metabolism. Molecular docking, molecular dynamics (MD) simulations and MST results revealed a strong binding affinity between pirfenidone and PDE1A. MD simulations showed the stability of the complex. It was observed that the RMSD analysis of the complex stabilized between 0.6 to 0.8 nm throughout the simulation, however RMSF showed minimal fluctuation. Data from the GSE226249 dataset confirmed that upregulation of PDE1A promotes fibrosis, whereas pirfenidone downregulates PDE1A, thereby exerting its antifibrotic effect. The inhibition of IPF progression by pirfenidone is mediated by PDE1A, providing insights into its therapeutic mechanism.